Description
This thesis elucidates the responsibility of the pharmaceutical industry for the current opioid epidemic, an epidemic which caused over 40,000 American deaths in 2016 alone. Twenty years prior, Purdue Pharma unleashed an extended-release formulation of the opioid oxycodone: OxyContin. With this, Purdue began a highly aggressive advertising campaign with the primary intention of guaranteeing the success of this drug; however, in doing so, they often neglected to ensure that the information they were propagating was wholly accurate. Previous reform attempts aimed at mollifying this crisis have ultimately fallen short, as they have failed to recognize the true extent of Purdue Pharma's involvement, especially with regard to the underlying issues that led to the initiation and progression of the epidemic. Future improvements should be targeted at the reform of regulatory agencies and insurance companies, as well as the cultural attitudes regarding pain and pain treatment that have been cultivated over the last several years. Ultimately, however, these reforms will likely prove to be insufficient unless the failings of the current healthcare system, including the pharmaceutical industry, are also taken into account.
Details
Title
- The Pharmaceutical Industry and the Opioid Epidemic: The Case of Purdue Pharma and OxyContin
Contributors
- Ozeran, Rachel Hoku Lii (Author)
- Fong, Benjamin (Thesis director)
- Brian, Jennifer (Committee member)
- School of Life Sciences (Contributor)
- Barrett, The Honors College (Contributor)
Date Created
The date the item was original created (prior to any relationship with the ASU Digital Repositories.)
2018-05
Subjects
Resource Type
Collections this item is in